A Role for the alpha 113 (GH1) Amino Acid Residue in the Polymerization of Sickle Hemoglobin

EVALUATION OF ITS INHIBITORY STRENGTH AND INTERACTION LINKAGE WITH TWO FIBER CONTACT SITES (alpha 16/23) LOCATED IN THE AB REGION OF THE alpha -CHAIN*

Mylavarapu V. S. Sivaram, Rajamani Sudha, and Rajendra P. RoyDagger

From the National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India

Received for publication, February 27, 2001, and in revised form, March 17, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

A cluster of amino acid residues located in the AB-GH region of the alpha -chain are shown in intra-double strand axial interactions of the hemoglobin S (HbS) polymer. However, alpha Leu-113 (GH1) located in the periphery is not implicated in any interactions by either crystal structure or models of the fiber, and its role in HbS polymerization has not been explored by solution experiments. We have constructed HbS Twin Peaks (beta Glu-6right-arrowVal, alpha Leu-113right-arrowHis) to ascertain the hitherto unknown role of the alpha 113 site in the polymerization process. The structural and functional behavior of HbS Twin Peaks was comparable with HbS. HbS Twin Peaks polymerized with a slower rate compared with HbS, and its polymer solubility (Csat) was found to be about 1.8-fold higher than HbS. To further authenticate the participation of the alpha 113 site in the polymerization process as well as to evaluate its relative inhibitory strength, we constructed HbS tetramers in which the alpha 113 mutation was coupled individually with two established fiber contact sites (alpha 16 and alpha 23) located in the AB region of the alpha -chain: HbS(alpha Lys-16right-arrowGln, alpha Leu-113right-arrowHis), HbS(alpha Glu-23right-arrowGln, alpha Leu-113right-arrowHis). The single mutants at alpha 16/alpha 23 sites were also engineered as controls. The Csat values of the HbS point mutants involving sites alpha 16 or alpha 23 were higher than HbS but markedly lower as compared with HbS Twin Peaks. In contrast, Csat values of both double mutants were comparable with or higher than that of HbS Twin Peaks. The demonstration of the inhibitory effect of alpha 113 mutation alone or in combination with other sites, in quantitative terms, unequivocally establishes a role for this site in HbS gelation. These results have implications for development of a more accurate model of the fiber that could serve as a blueprint for therapeutic intervention.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Sickle cell anemia is a consequence of a point mutation (Glu-6right-arrowVal) at the sixth position in the beta -chain of the hemoglobin molecule (1). The replacement of a charged residue with a hydrophobic one on the surface of the protein drastically reduces the solubility of the deoxygenated sickle hemoglobin (HbS)1, leading to its polymerization into long helical fibers that are responsible for the clinical manifestations of sickle cell disease. Electron microscopy and crystallographic studies have suggested that both the deoxy HbS crystal and fiber are constructed from the same "Wishner-Love" double strands (2-5). The model of the fiber structure derived from these analyses consists of seven Wishner-Love double strands (6-9).

The polymerization process is triggered by lateral interactions of the donor Val-6beta of a tetramer of one strand of the double strand with the acceptor pocket at the EF corner (elicited mainly by beta Phe-85 and beta Leu-88) of the beta -chain of an adjacent molecule present in the second strand of the double strand. Subsequent intra-double strand and inter-double strand interactions involving several amino acid residues from both alpha - and beta -chains contribute to the stabilization of the fiber structure. The polymerization-impairing or -enhancing propensity of mutant hemoglobins, in a binary mixture of mutant hemoglobins and HbS, has facilitated the mapping of several contact residues of the HbS polymer (10-12). The list of contact sites has been expanded by subsequent studies involving chemical modifications of HbS (13, 14) and site-directed mutagenesis (15-19). However, the identities of all the fiber contacts that are predicted by model studies have not yet been tested in solution experiments. The fiber models themselves are not perfect, because they include several polymerization-insensitive sites, exclude polymerization-sensitive sites, and possibly underestimate or overestimate the number of contact residues (6-9). Thus, it is prudent to identify and authenticate all of the participating residues by solution polymerization studies. More importantly, knowledge of the inhibitory strength of each contact site and the combinatorial effects of two or more contact sites (interaction linkage) is imperative for designing effective antisickling agents or vectors for gene therapy that could bring about optimum inhibition of fiber formation needed for clinical amelioration of sickling. The relative strength of contact sites, as well as their "interaction linkage" relationships in terms of synergy and/or additivity, is largely unknown and is beginning to be addressed only now by solution polymerization studies (20).

We have chosen three sites, namely alpha 16, alpha 23, and alpha 113, for further delineation of their contributions to the polymerization of HbS. Whereas sites alpha Lys-16 and alpha Glu-23, located in the AB region, are established contact points in the HbS polymer, the participation of alpha Leu-113 (GH1) in the polymerization process is unknown. The alpha 113 site is of interest because of its unique structural location. First, alpha 113 is in sequence contiguity with a cluster of GH corner residues, alpha 114, alpha 115, and alpha 116, which are established or implicated intra-double strand contact sites of the HbS fiber (7, 11, 16). Second, the three-dimensional structure of the hemoglobin brings the AB region of the alpha -chain in close proximity to the GH corner. The involvement of several residues of the AB corner (alpha 16, alpha 20, alpha 23) in HbS polymerization has been deduced from crystal structures and also been validated in solution experiments (21-24). However, alpha Leu-113, which is located in the periphery of several physiologically relevant axial contacts in the AB-GH region, is not implicated in any contacts by crystal or model studies. Interestingly, a natural Hb variant at this site, Hb Twin Peaks (alpha Leu-113right-arrowHis), is reported (25), but the functional properties of Hb Twin Peaks or its participation in deoxy HbS polymerization has not been examined. Here, we constructed HbS Twin Peaks (alpha Leu-113right-arrowHis, beta Glu-6right-arrowVal) to establish the role of the alpha 113 site in HbS fiber generation. Furthermore, we have combined the alpha 113 mutation at the GH corner with mutations of contact sites involving residues alpha 16 and alpha 23 of the AB region to see whether the inhibitory sites in the "contact-rich" AB-GH domain have additive or synergistic influence on the Val-6beta -dependent polymerization of HbS.

We have adopted a chemo-enzymatic strategy for the construction of alpha -globin mutants. The propensity of V8 protease to catalyze the ligation of complementary fragments, alpha 1-30 and alpha 31-141, to generate a full-length alpha -globin (alpha 1-141) has been utilized for this purpose (26). Appropriate synthetic alpha 1-30 segments were employed to incorporate desired mutations at sites alpha 16 and alpha 23. The Hb Twin Peaks mutation was introduced through the alpha 31-141 segment of the marmoset (Callithrix argentata) alpha -chain, which contains a single amino acid substitution, alpha Leu-113right-arrowHis, with respect to the human alpha 31-141 segment (27). HbS tetramers were assembled from beta s-chain and respective single and double mutant alpha -chains. The structural/conformational, functional, and polymerization behavior of mutants was studied with a view to examining the hitherto unknown role of the alpha 113 (GH1) site in the HbS gelation process as well as to quantifying its inhibitory strength relative to selected AB region alpha -chain contact residues.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

CM-52 and DE-52 were purchased from Whatman. V8 protease was obtained from Pierce. The chemicals used in peptide synthesis were from Novabiochem. All other chemicals and reagents were of analytical purity and procured from standard commercial sources. The hemoglobins from sickle cell patients and marmosets were purified form respective red cell hemolysates by established procedures employing successive anion (DE-52) and cation (CM-52) exchange chromatography. The hydroxymercuribenzoate alpha - and beta -chains were prepared as described previously (28). The chains were freed from heme by acid-acetone precipitation.

Preparation of alpha 1-30 and alpha 31-141 Segments of Human or Marmoset alpha -Globin-- The complementary segments of alpha -globin needed for the semisynthesis of mutant chains were prepared by V8 protease digestion (26). The respective globins were dissolved in 10 mM ammonium acetate buffer (pH 4) at a concentration of 0.5 mg/ml and digested at 37 °C with V8 protease (1:200, w/w) for 3 h. The completion of digestion was ascertained by RPHPLC. The complementary segments, alpha 1-30 and alpha 31-141, from the respective digestion mixtures were isolated in pure form by gel permeation chromatography on a Sephadex G50 column. The column was equilibrated and run in 0.1% trifluoroacetic acid. The lyophilized sample of the digest was dissolved in the above solvent and loaded on to the column. The column was run at a flow rate of 45 ml/h, and the elution profile was monitored at 280 nm. The individual chromatographic profile of the alpha -globin digest (human or marmoset) showed only two peaks, alpha 31-141 and alpha 1-30, as expected from a single cleavage at the 30-31 peptide bond. The peak fractions from each digest were pooled separately and lyophilized.

Synthesis of alpha 1-30 Analogs: alpha (Lys-16right-arrowGln) and alpha (Glu-23right-arrowGln)-- Peptides were synthesized by a standard solid phase N-(9-fluorenyl)methoxycarbonyl (Fmoc) strategy on a peptide synthesizer (model 90, Advanced Chemtech). For this, Wang resin pre-loaded with N-alpha -Fmoc-Glu was used as the starting material. The stepwise coupling of Fmoc amino acids was performed with the N,N'-diisopropylcarbodiimide/1-hydroxybenzotriazole activation procedure. The coupling of each step was monitored by a Kaiser test (29), and wherever necessary, a double coupling was used to increase the yield. On completion of the synthesis, the N-terminal Fmoc group was removed using piperidine. The peptides were cleaved from the resin and deprotected with an appropriate volume of a mixture containing trifluoroacetic acid, ethanedithiol, phenol, thioanisole, and water (80:5:5:5:5, v/v). The resin was removed by filtration, and the crude cleaved peptides were precipitated using cold diethyl ether. The peptides were purified by RPHPLC, and their chemical identity was checked by electrospray mass spectrometry. The experimental masses of the peptides were in agreement with their theoretical masses: alpha (Lys-16right-arrowGln), observed mass of 3040.73 Da (theoretical mass, 3040.73); alpha (Glu-23right-arrowGln), observed mass of 3040.50 (theoretical mass, 3039.39).

Construction of Mutant alpha -Globins-- V8 protease-mediated semisynthesis of alpha -globin was carried out at 4 °C in 50 mM ammonium acetate buffer (pH 6) containing 30% 1-propanol. For this, the lyophilized samples of natural or synthetic analogs of alpha 1-30 and human or marmoset alpha 31-141 were individually prepared in water. Suitable volumes of the complementary fragments were mixed to obtain a 1:1 molar ratio and lyophilized. The lyophilized material (150 mg) was dissolved in 6 ml of 84 mM ammonium acetate buffer (pH 6). To this solution, 3 ml of 1-propanol was added. The mixture was cooled on ice, subsequent to which 1 ml of V8 protease solution (1.5 mg/ml prepared in water) was added. The ligation reaction mixture was incubated at 4 °C for 24 h. The reaction was stopped by addition of 2 ml of 5% trifluoroacetic acid and lyophilized. The semisynthetic alpha -globin was isolated from the mixture by CM52-urea chromatography, extensively dialyzed against 0.1% trifluoroacetic acid, and lyophilized (26). The semisynthetic yield of the protein varied between 35 and 45%. The identity of the alpha -globin constructs were checked by mass spectrometry and tryptic peptide mapping.

Reconstitution of alpha -Globin and the beta s-Chain into HbS Tetramers-- The semisynthetic alpha -globin was reconstituted with heme and the beta s-chain into tetrameric hemoglobin through the "Alloplex pathway" as described previously (26). The reconstituted tetramers were purified by CM-52 chromatography. The heme stoichiometry in purified tetramers was ascertained by 280:540 nm absorbance ratios. The A280:A540 ratio for native HbS was 2.54. For reconstituted tetramers, this ratio varied between 2.49 and 2.55. The tetramers were checked for the correct stoichiometry of chains by RPHPLC. The alpha - and beta -chains from each Hb were isolated and subjected to electrospray mass spectrometry and tryptic peptide mapping to ensure that the reconstitution procedure did not alter the chemical integrity of the chains.

Spectroscopic Studies-- The spectra were recorded on a Lambda Bio20 spectrophotometer (PerkinElmer Life Sciences). The UV region-derivative spectra were recorded in the first derivative mode of the spectrophotometer. The hemoglobin concentration used for the spectral measurements was ~50 µM on heme basis.

Circular dichroism spectra were recorded on a J710 spectropolarimeter (Jasco) fitted with a Peltier-type constant temperature cell holder (PTC-348W). The calibration of the equipment was done with (+)-10-camphorsulfonic acid.

Analytical Procedures-- The synthetic peptides were purified by RPHPLC on an aquapore RP300 column (250 × 7 mm) using a 4-72% linear gradient of solvent B (acetonitrile containing 0.1% trifluoroacetic acid) in 130 min at a flow rate of 2 ml/min. Globin chains from respective hemoglobins were separated on a similar column of a smaller dimension (250 × 4.6 mm) under identical conditions but at a flow rate of 0.7 ml/min.

Analytical anion-exchange chromatography of HbS constructs was performed by FPLC (AKTA, Amersham Pharmacia Biotech) on a Mono Q HR5/5 column. The respective protein samples were prepared in Tris acetate buffer (50 mM, pH 8.5) and loaded on the column that was pre-equilibrated with the same buffer. The samples were chromatographed using a linear pH gradient of 50 mM Tris acetate buffer, pH 8.5 to 7.0 over 20 min with a 1 ml/min flow rate. The elution profile was monitored at 540 nm.

Electrospray mass spectrometric analysis was carried out on a VG Platform (Fisons) mass spectrometer. The instrument was usually calibrated with standard myoglobin solution. Appropriate amounts of globin chains isolated from each HbS sample by RPHPLC were taken in 50% acetonitrile containing 1% formic acid and analyzed under the positive ion mode. The spectra of globins produced a series of protonated species typically ranging from 13 to 22 positive charges. The average molecular mass of each globin from the respective spectra was obtained by using the software provided by the manufacturer.

Oxygen Affinity Measurements-- The oxygen affinity of hemoglobins was measured by a Hemox-Analyzer (TCS Medical Products, New Hope, PA) at 29 °C in 0.1 M sodium phosphate buffer, pH 7.4. The hemoglobin concentration was ~0.1 mM based on heme. The P50 value (partial oxygen pressure at 50% saturation) and the Hill coefficients (nmax), a measure of cooperativity, were determined from each dissociation curve.

Measurement of Gelation Concentration, Csat-- The gelation concentration of HbS constructs was determined by the dextran-Csat method of Bookchin et al. (30). This method allows measurement of Csat under near-physiological conditions and at a much lower concentration of HbS (about 5-fold or less) than that required in standard Csat assays but essentially provides the same information. Briefly, a suitable aliquot of a concentrated solution of hemoglobin in potassium phosphate buffer (0.05 M, pH 7.5) was taken in a 1.5-ml microcentrifuge tube. A concentrated dextran (70 KDa) solution prepared in the same buffer was added to the aliqout and mixed well. This mixture was overlaid with 0.5 ml of mineral oil, chilled on an ice bath, and deoxygenated with an anaerobically prepared dithionite solution through an airtight Hamilton syringe. The final concentrations of dextran and dithionite in the mixture were 120 mg/ml and 0.05 M, respectively. The above deoxygenated sample was allowed to polymerize at 37 °C for 30 min, after which the gel under the oil layer was disrupted with the plunger of a Hamilton syringe. The tube was centrifuged at room temperature at 14,000 rpm for 30 min. The above process of gel disruption and centrifugation was repeated twice, subsequent to which the oil layer was aspirated, and suitable aliquots from the supernatant were taken for estimation of Csat by Drabkin's reagent.

Kinetics of Polymerization-- The delay time kinetics of deoxyhemoglobin were studied in 1.8 M phosphate buffer (pH 7.25) as described by Adachi and Asakura (31, 32) using a Cary 400 spectrophotometer equipped with a Peltier temperature controller. The polymerization of deoxyhemoglobin samples was initiated by a temperature jump from 4 to 30 °C within 10 s, and the progress of the reaction was followed by monitoring turbidity changes at 700 nm. The delay time was calculated from the kinetic traces.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Assembly and Chemical Characterization of HbS Twin Peaks (alpha Leu-113right-arrowHis, beta Glu-6right-arrowVal)-- The construction of the alpha -chain of Hb Twin Peaks (alpha Leu-113right-arrowHis) through the alpha -globin semisynthetic strategy involves the stitching of human alpha 1-30 with an alpha 31-141 segment containing the Twin Peaks mutation. The two peaks isolated from G-50 chromatography of the V8 protease digest of the marmoset alpha -globin were subjected to electrospray mass spectrometry. The reported sequence of marmoset alpha -globin (27) contains amino acid substitutions at four sites compared with the human (T8S, A19S, E23D, and L113H). The experimental masses obtained for the two peaks, 3029.23 and 12126.05 Da, respectively, were in agreement with the calculated masses of the complementary fragments of marmoset alpha -globin (alpha 1-30, 3028.32 Da; alpha 31-141, 12127.99 Da).

The semisynthetic Twin Peaks alpha -globin was obtained by ligation of human alpha 1-30 and marmoset alpha 31-141 fragments through the V8 protease-catalyzed reaction as described under "Materials and Methods." The purified material was reconstituted with the beta s-chain and heme to obtain the tetramer. HbS Twin Peaks was isolated in pure form CM-52 chromatography. The purity of the protein was further established by FPLC. Under identical chromatographic conditions, HbS Twin Peaks eluted slightly earlier than the native HbS from the Mono Q anion-exchange column (Fig. 1). This elution behavior of HbS Twin Peaks is consistent with the replacement of Leu by His at the alpha 113 site in HbS.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 1.   FPLC of HbS Twin Peaks (alpha Leu-113right-arrowHis). A sample of the mutant HbS was chromatographed on a Mono Q (HR5/5) column using the AKTA system of Amersham Pharmacia Biotech. The protein sample was prepared in 50 mM Tris acetate buffer (pH 8.5) and loaded on to the column. The elution of Hb was carried out using a linear pH gradient of the above buffer (pH 8.5-7.0) over a period of 20 min at a flow rate of 1 ml/min. The elution profile was monitored at 540 nm. Broken line, HbS; continuous line, HbS Twin Peaks. The inset shows the RPHPLC separation of the globin chains of HbS Twin Peaks and native HbS. The purified samples of each hemoglobin were analyzed on an RP300 column (250 × 4.6 mm) using a 4-72% gradient of acetonitrile containing 0.1% trifluoroacetic acid in 130 min at a flow rate of 0.7 ml/min.

The purified HbS Twin Peaks was analyzed by reverse-phase HPLC to establish the stoichiometry and chemical integrity of the globin chains. The alpha - and beta -chains of HbS Twin Peaks were separated on a C8 column (RP300) using an acetonitrile- trifluoroacetic acid-water solvent system and compared with native HbS. The chromatographic profile showed identical retention times for beta s-chains from both samples and indicated correct stoichiometry of the alpha - and beta -chains in HbS Twin Peaks (Fig. 1, inset). Interestingly, the order of elution of chains of HbS Twin Peaks was reversed as compared with natural HbS. The alpha -chain of HbS Twin Peaks eluted earlier than the beta s-chain, suggesting that Leu to His substitution exerted considerable influence on the chromatographic behavior of the alpha -chain. To rule out the possibility that the above elution behavior was a consequence of chemical modifications during semisynthesis or tetramer assembly, alpha - and beta s-chains of HbS Twin Peaks were isolated by reverse-phase HPLC and subjected to electrospray mass spectrometry. The molecular mass of the isolated alpha -chain (15150.03 Da) obtained by electrospray mass spectrometry agreed very well with the calculated value of 15150.36 Da for the alpha -chain of Hb Twin Peaks. Likewise, the experimental mass of the beta -chain (15837.99 Da) was in accord with the calculated mass of the beta s-chain (15837.25 Da). Taken together, the results unambiguously established the chemical integrity of HbS Twin Peaks.

Structural Characterization of HbS Twin Peaks-- The CD spectrum (Fig. 2) in the soret region for HbS Twin Peaks was similar to that of the HbS, suggesting that interactions of heme with the relevant aromatic residues in the mutant protein are maintained and that the Leu-113right-arrowHis mutation does not have a deleterious effect on the folding of the heme pocket.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2.   Soret region CD spectra of HbS Twin Peaks. The spectra were recorded at 10 °C in 10 mM potassium phosphate buffer (pH 7.4) using a 1-mm path length cell. The hemoglobin concentration was 0.64 mg/ml. Solid line, HbS; broken line, HbS Twin Peaks. MRE, mean residue ellipticity.

UV spectroscopy was employed to further probe the quaternary structural status of HbS Twin Peaks. The ligand-dependent fine spectral changes around 290 nm are considered as diagnostic of the quaternary structure of the Hb molecule (33-35). The first derivative UV spectra of oxy (liganded) and deoxy (unliganded) forms of HbS Twin peaks and native HbS were compared to assess the presence of gross quaternary structural changes, if any, in HbS Twin Peaks (Fig. 3). Both HbS and HbS Twin Peaks displayed fine structural characteristics with a peak at 289 nm and a double minimum at 285 and 293 nm, respectively. In both Hbs, the magnitude of the double minimum was reduced to about half upon deoxygenation. These results suggest that quaternary structural features of native HbS are preserved in HbS Twin Peaks.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   First derivative UV spectra of liganded and unliganded HbS Twin Peaks. The spectra of oxy and deoxy forms of the protein were recorded at 25 °C in the first derivative mode of the spectrophotometer. The hemoglobin concentration used was about 50 µM (on heme basis) in 10 mM potassium phosphate buffer (pH 7.4) containing 0.1 M chloride. Solid lines and broken lines represent the spectra of deoxy and oxy forms of the hemoglobin, respectively. 1, native HbS; 2, HbS Twin Peaks.

Oxygen Affinity of HbS Twin Peaks-- The functional aspect of HbS Twin Peaks was assessed by measuring the oxygen affinity at pH 7.4 in 0.1 M sodium phosphate buffer at 29 °C using a Hemox Analyzer. P50 of HbS Twin Peaks was found to be 8, against 8.5 for a control sample of native HbS. The Hill coefficient (nmax) value for HbS Twin Peaks (2.4) was comparable with that of native HbS (2.5). Thus the mutant Hb exhibited normal oxygen binding and cooperativity, suggesting that the alpha Leu-113right-arrowHis substitution did not cause any significant perturbation of the quaternary structure of the protein. This interpretation is consistent with the above spectroscopic studies of HbS Twin Peaks.

Polymer Solubility of HbS Twin Peaks-- The gelation concentration (Csat) of HbS Twin Peaks was measured in the presence of high concentrations of dextran developed by Bookchin et al. (30) and as described under "Materials and Methods." We carried out the polymerization of deoxygenated tetramers, HbS Twin peaks and native HbS, under identical conditions and subsequently measured the concentration of the respective hemoglobins in the supernatants to obtain their polymer solubility (Fig. 4). The native HbS yielded a Csat of 29-31 mg/ml in the initial concentration range of 50-80 mg/ml HbS. In contrast, the Csat values for HbS Twin Peaks at the initial concentrations of 70 and 80 mg/ml were 53 and 55 mg/ml, respectively. Thus the polymer solubility of HbS Twin Peaks was considerably higher (about 1.8-fold) as compared with that of HbS. To further confirm that the observed Csat was specific to HbS Twin Peaks, we constructed an HbA counterpart of Twin Peaks. This Hb was assembled from the Twin Peaks alpha -chain and beta A-chain (Glu-6beta ) through the same procedure as that employed for the assembly of HbS Twin Peaks. Under similar assay conditions, HbA or HbA Twin Peaks did not polymerize when tested at an initial concentration of 70 mg/ml, suggesting that the Csat values of HbS Twin Peaks reflect the true potential of the alpha 113 site to inhibit beta s-dependent polymerization of HbS.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 4.   Polymer solubility of HbS Twin Peaks. The measurements were performed in the presence of dextran in 50 mM potassium phosphate buffer (pH 7.5) and at 37 °C as described under "Materials and Methods." The hemoglobin concentration in the supernatant (Csat) was determined by Drabkin's method. open circle , HbS; triangle , HbS Twin Peaks.

Kinetics of Polymerization-- To further authenticate the participation of the alpha 113 site in the HbS gelation process, kinetics of polymerization of HbS Twin Peaks, HbS, HbA Twin Peaks, and HbA were studied in 1.8 M phosphate buffer (Fig. 5). Two concentrations (0.5 and 0.78 mg/ml) of HbS Twin Peaks were tested. HbS Twin Peaks polymerized with a longer delay time as compared with HbS at both concentrations. The delay time for HbS Twin Peaks at an initial concentration of 0.5 mg/ml was about 18 min compared with 12 min for HbS (Fig. 5a). At a higher concentration (0.78 mg/ml), the delay time of HbS Twin Peaks polymerization decreased to 8 min, which was still higher compared with HbS (6 min) at the same concentration (Fig. 5b). In contrast, HbA Twin Peaks and HbA did not polymerize at an initial Hb concentration of 1 mg/ml (Fig. 5a).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Kinetics of polymerization of HbS Twin Peaks. Polymerization of hemoglobins was carried out in 1.8 M potassium phosphate buffer, pH 7.25. The polymerization of the deoxy form of the protein was initiated by a temperature jump from 4 to 30 °C within 10 s, and the progress of the reaction was continuously monitored at 700 nm. a, x---x, HbS (0.5 mg/ml); open circle - - -open circle , HbS Twin Peaks (0.5 mg/ml); ---, HbA (1 mg/ml); x- - -x, HbA Twin Peaks (1 mg/ml). b, x---x, HbS (0.78 mg/ml); open circle - - -open circle , HbS Twin Peaks (0.78 mg/ml).

Assembly of HbS Tetramers from the beta s-Chain and Mutant alpha -Chains (Lys-16right-arrowGln; Glu-23right-arrowGln; Lys-16right-arrowGln, Leu-113right-arrowHis; Glu-23right-arrowGln, Leu-113right-arrowHis)-- To see whether the inhibitory potential of the alpha 113 site in the deoxy-HbS fiber could exert a synergistic or additive effect when combined with surrounding intermolecular contact residues of the AB region of the alpha -chain, we generated HbS tetramers with double mutant alpha -chains that contained amino acid substitutions at alpha 16 (Lysright-arrowGln) or alpha 23 (Gluright-arrowGln) positions along with the Twin Peaks mutation, alpha 113 (Leuright-arrowHis). HbS mutants with single amino acid replacements at the above selected AB region sites (alpha 16 and alpha 23) were also constructed to evaluate the quantitative strength of each of these sites vis à vis their relative contributions to the polymerization reaction and the extent of interaction linkage, if any, with the alpha 113 site located at the GH corner.

The role of the alpha 16 site in the polymerization of HbS has been established by solution studies (21) with Hb variants, I (Lys-16alpha right-arrowGlu). In our studies, we incorporated Gln rather than Glu in the place of Lys at the alpha 16 position, considering the susceptibility of Glu residues to V8 protease hydrolysis during the ligation reaction. The secondary hydrolysis at Glu-16 during the proteo-synthesis of the 30-31 peptide bond between alpha 1-30 (Lys-16right-arrowGlu) and alpha 31-141 fragments would lower the yield of the semisynthetic alpha -globin. Moreover, the presence of Gln is unlikely to affect the overall structure and function of the tetramer, because Hb Beijing, which contains a conservative residue (Lys-16right-arrowAsn) at this site, exhibits normal stability and does not cause any hematological complications in the heterozygotes (36). The Glu-23right-arrowGln substitution present in the alpha -chain of Hb Memphis was retained, because it was compatible with the alpha -globin semisynthetic strategy.

The desired substitutions in alpha -chains were introduced through the semisynthetic strategy described under "Materials and Methods" and as applied to the construction of the alpha -chain of Twin Peaks. The HbS tetramers reconstituted from the respective semisynthetic alpha -chains and beta s-chain were purified by cation exchange CM-52 chromatography. The purity of the HbS constructs were further tested by anion-exchange chromatography on a Mono Q column using FPLC (data not shown). The FPLC profile displayed a single peak in all cases, establishing the homogeneity of each preparation. The elution pattern of the proteins was in accord with the charge difference created because of amino acid replacement(s).

The separation of chains by reverse-phase HPLC showed the presence of a 1:1 stoichiometry of alpha - and beta s-chains in all the HbS constructs. The order of elution of chains from HbS carrying single mutations (alpha 16 or alpha 23) was similar to HbS; alpha -chains carrying either point mutation eluted later than the beta s-chain, suggesting that the Lys-16right-arrowGln or Glu-23right-arrowGln substitution does not cause a significant alteration of the behavior of alpha -chains on reverse-phase columns. In contrast, the chromatographic pattern of double mutants exhibited a reversal of elution order that was reminiscent of HbS Twin Peaks. In both HbS double mutants (Lys-16right-arrowGln, Leu-113right-arrowHis or Glu-23right-arrowGln, Leu-113right-arrowHis), the alpha -chains eluted before the beta s-chains. Thus the presence of His at the 113 site alone seems to dictate the behavior of alpha -chains on reverse-phase columns. The experimental electrospray masses of isolated chains from each HbS sample were in good agreement with their respective theoretical masses (Table I).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Electrospray mass of isolated globin chains from mutant HbS constructs
The globin chains were isolated by RPHPLC of respective tetramers and subjected to electrospray mass spectrometry analysis. The values in daltons represent the average mass based on natural isotopic abundance. The theoretical mass (calculated) of each chain is indicated in parentheses.

Functional Characterization-- The oxygen affinities of all of the HbS mutants (Table II) were in the normal range (P50 = 7.0-7.5), albeit slightly higher than that of native HbS (P50 = 8.5). Hill coefficients of all of the mutants were also normal, indicating preservation of HbS-like quaternary structure. HbS I (alpha Lys-16right-arrowGlu) has been studied previously and found to exhibit the usual functional properties (21). The normal oxygen binding behavior of mutants, HbS(alpha K16Q) or HbS(alpha K16Q,L113H), suggests that abrogation of the positive charge or reversal of the charge polarity at the alpha 16 site does not appreciably affect the oxygen binding behavior of the Hb.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Influence of alpha -chain mutations on the oxygen affinity and polymer solubility of HbS constructs

Polymer Solubility of the Mutants-- The Csat values of all HbS constructs were obtained in the presence of dextran under similar conditions as those used for HbS Twin Peaks. The Csat values of the single as well as double mutants were significantly higher than the Csat of native HbS, albeit to different extents (Table II). The innate Csat of HbS (30 mg/ml) increased by nearly 30% (39 mg/ml) and 49% (44 mg/ml) with point mutations of alpha 16 and alpha 23 sites, respectively. This increase in Csat for the above mutants was markedly less than that observed for HbS Twin Peaks; Csat of HbS Twin Peaks (53 mg/ml) was about 80% higher relative to native HbS. The Csat of the double mutant comprising sites alpha 16 and alpha 113 (60 mg/ml) was twice that of HbS and significantly higher than that of the mutation of the alpha 113 site alone. In contrast, the double mutant consisting of alpha 23 and alpha 113 sites produced a Csat (55 mg/ml) that was very similar to that of HbS Twin Peaks.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

A 14-strand model of the HbS fiber composed of seven Wishner-Love double strands and stabilized by intra- and inter-double strand interactions is now well accepted, although ambiguities persist regarding the arrangement of the crystal double strands within the fiber (9). Whereas intra-double strand contacts of the fiber are similar to those found in the single crystals of HbS, inter-double strand contacts are somewhat different. This is due to the fact that double strands in the crystal are straight, whereas packing requirements entail twisted strands. The map of contact sites displayed by different fiber models varies considerably depending on the distance of separation used between Wishner-Love double strands to achieve a reasonable packing (6-8). Most of the interactions within the double strand consist of residues from the beta -chain, and those involved between the double strands emanate predominantly from the alpha -chains. In this connection, it is noteworthy that the discrepancies between the molecular modeling and solution experiments largely relate to the contact sites involving alpha -chain residues. Therefore, further delineation of interactions in the HbS fiber, particularly of those surface residues of the alpha -chain that are not implicated in contacts by fiber models or solution studies, appears to be necessary, because it is likely to provide information on the inter-double strand contacts specific to the fiber. The major aim of the present study was to explore the role of one such residue, alpha Leu-113 (GH1), by solution polymerization experiments.

We chose to replace the Leu residue at the alpha 113 site by His because this point mutation is present in the alpha 31-141 segment of the marmoset alpha -chain and was compatible with our semisynthetic strategy. Because this mutation (alpha Leu-113right-arrowHis) is also naturally present in Hb Twin Peaks (25), it would be expected to have no effect on hemoglobin stability and function. Indeed, the environment of heme and the alpha 1beta 2 interface in HbS Twin Peaks was found to be similar to that in HbS, indicating that HbS Twin Peaks assumes an HbS-like quaternary structure. The P50 and Hill coefficient of HbS Twin Peaks were also similar to those of HbS. Thus, the inhibition of polymerization seen with HbS Twin Peaks, both in high phosphate buffer and in the presence of dextran, reflects the true inhibitory potential of the alpha 113 residue.

The participation of the alpha 113 site in the polymerization of HbS was further corroborated by the polymer solubility data of double mutants involving sites alpha 113 and alpha 23 or alpha 16. The dextran Csat of point mutants at alpha 16 or alpha 23 (39 and 44 mg/ml, respectively) was much lower than the Csat of HbS Twin Peaks (alpha 113; 53 mg/ml), suggesting that the above AB region alpha -chain residues are relatively weak fiber contacts as compared with the alpha 113 site. In contrast, the Csat of the double mutants comprising sites alpha 16 and alpha 113 (60 mg/ml) or alpha 23 and alpha 113 (55 mg/ml) was higher than or comparable with that of HbS Twin Peaks. Thus, the inhibitory effect of alpha 113 was additive with alpha 16 but not with alpha 23. This is in accord with the crystal structure of deoxy HbS, which shows axial interactions of alpha Lys-16 with alpha Pro-114 and alpha Ala-115 residues located at the GH corner (37). The interactions of Lys-16 are likely to be perturbed by Gln mutation. Indirect effects of Lys-16 replacements on the alpha 113 mutation are also conceivable in view of the sequence proximity of alpha 113 to the above GH corner sites. In contrast, interactions of the alpha Glu-23 site do not involve the GH corner residues.

The evaluation of the individual strength of contact sites in quantitative terms has been a current subject of intense focus. In recent studies, site-directed mutagenesis has been employed to generate perturbation in both alpha - and beta -chain contact points with sites in question mutated individually or in combination. The alpha -chain contacts have also been probed through construction of interspecies hybrids and semisynthetic chimeric hemoglobins (38-40). Nonetheless, these interspecies hybrids contain a large number of mutations, at contact sites or otherwise, compared with the human alpha -chain, that interfere with the unambiguous assignment of the role of each residue vis à vis the synergistic and additive nature of their interactions. Given the large number of participating residues and the complexity of the polymerization process, precise delineation of the individual or combinatorial strength of sites could be ideally achieved by systematic variation of surface residues through DNA-based site-directed mutagenesis (16, 18, 19, 41). The semisynthetic method, although restricted in scope, could also be effectively applied in appropriate situations as demonstrated in the present study.

We are now in a position to compare the individual strength of alpha 113, alpha 16, and alpha 23 sites with other sites and also the interaction linkage of some fiber contacts in quantitative terms (Table III), because the Csat values of respective HbS mutants in all these cases have been determined in the presence of dextran under similar conditions, as described by Bookchin et al. (30). The inhibitory strength of sites varies as follows: beta 95 > beta 88 > alpha 113 ~ alpha 85 > alpha 23 > alpha 16. The inhibitory strength of alpha 113 is similar to that of alpha 85 but significantly lower than that of beta 95 or beta 88. The other two sites, alpha 16 and alpha 23, are rather weak. Among the above sites, beta 95 and alpha 85 residues are implicated in inter-double strand contacts, whereas beta 88 is involved in crucial primary interactions with Val-6beta . We envision the alpha 113 site as a potential inter-double strand contact point of the fiber, because it is not implicated in interactions by crystal and model studies. The remaining two sites (alpha 16 and alpha 23) with lowest inhibitory propensity are intra-double strand contacts. Against this scenario, it appears that the inhibitory strength of fiber-specific inter-double strand contact sites is likely to be greater than those involved in intra-double strand contacts. It is instructive to note that multiple mutations of the inter-double strand contacts in the pig alpha -chain relative to human were posited as prime sites that contributed to the total abrogation of polymerization in interspecies hybrid HbS composed of pig alpha -chain and human beta s-chain (38). The influence of simultaneous perturbation of two or more contact sites has been analyzed in quantitative terms only for a few combinations of sites. Whereas a non-additive inhibitory effect was seen for beta 88/beta 95 residues, the potentiation of polymerization by alpha 6/alpha 75/beta 121 appeared to be additive. Our data show that the inhibitory effect of the alpha 113 site was non-additive with alpha 23 but additive with alpha 16. So far, a synergistic influence between two contact sites has not been demonstrated in any definitive fashion. The knowledge of the individual strength of all of the fiber contact sites in quantitative terms appears to be an immediate need, because it would help discriminate weak and strong sites, thereby restricting the number of combinations that could be assessed as potential therapeutic targets.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Quantitative strength of contact sites of HbS fiber measured by the dextran Csat method
The Csat values for the listed sites were determined in the presence of dextran under similar conditions except for minor differences related to the estimation of supernatant Hb concentration subsequent to gelation. Whereas Csat values of HbSs containing mutations at sites alpha 16, alpha 23, alpha 113, alpha 16/113, and alpha 23/113 (present study) were obtained by measuring the Hb concentration in the supernatant by Drabkin's procedure, concentration estimates in the case of other sites (Csat values represented in parentheses) were made by quantitative amino acid analysis. The apparent difference between Csat values of HbS (Val-6beta ) obtained in the present report (30 mg/ml) and the previous studies (34 mg/ml) is presumably related to the method of Hb estimation. Nonetheless, this small difference may not have a bearing on the comparative analyses of Csat data.

In conclusion, we unequivocally established a role for the alpha 113 amino acid residue in the polymerization of HbS. We not only demonstrated the participation of this site in the gelation process but also quantified its strength of interaction. The alpha 113 amino acid residue is not postulated in any interactions in the crystal structure of HbS and is also excluded by the models of the fiber. These considerations lead us to believe that the alpha 113 site might be involved in fiber-specific inter-double strand contacts. Further solution copolymerization studies of HbS Twin Peaks coupled with electron micrographic analysis of the HbS Twin Peaks fiber should help delineate the stereochemistry of the alpha 113 residue in the polymer and facilitate efforts to develop an accurate model of the HbS fiber.

    ACKNOWLEDGEMENTS

We thank Prof. Sandip K. Basu for interest in this work and Dr. Debasisa Mohanty for helpful discussions. The SS blood sample was kindly provided by Dr. V. S. Dani of Indira Gandhi Medical College, Nagpur, India.

    FOOTNOTES

* This work was supported by a grant from the Department of Science and Technology (to R. P. R.) and grants to the National Institute of Immunology from the Department of Biotechnology, Government of India.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Fax: 91-11-610-9433; E-mail: rproy@nii.res.in.

Published, JBC Papers in Press, March 20, 2001, DOI 10.1074/jbc.M101788200

    ABBREVIATIONS

The abbreviations used are: HbS, sickle hemoglobin; HPLC, high pressure liquid chromatography; RPHPLC, reverse phase HPLC; Fmoc, N-(9-fluorenyl)methoxycarbonyl; FPLC, fast protein liquid chromatography.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Ingram, V. M. (1956) Nature 178, 792-794
2. Padlan, E. A., and Love, W. E. (1985) J. Biol. Chem. 260, 8272-8279[Abstract/Free Full Text]
3. Padlan, E. A., and Love, W. E. (1985) J. Biol. Chem. 260, 8280-8291[Abstract/Free Full Text]
4. Dykes, G. W., Crepeau, R. H., and Edelstein, S. J. (1978) Nature 272, 506-510[Medline] [Order article via Infotrieve]
5. Dykes, G. W., Crepeau, R. H., and Edelstein, S. J. (1979) J. Mol. Biol. 130, 451-472[Medline] [Order article via Infotrieve]
6. Watowich, S. J., Gross, L. J., and Josephs, R. (1989) J. Mol. Biol. 209, 821-828[Medline] [Order article via Infotrieve]
7. Cretegny, I., and Edelstein, S. J. (1993) J. Mol. Biol. 230, 733-738[CrossRef][Medline] [Order article via Infotrieve]
8. Watowich, S. J., Gross, L. J., and Josephs, R. (1997) J. Struct. Biol. 111, 161-179[CrossRef]
9. Eaton, W. A., and Hofrichter, J. (1990) Adv. Protein Chem. 40, 63-279[Medline] [Order article via Infotrieve]
10. Nagel, R. L., Johnson, J., Bookchin, R. M., Garel, M. C., Rosa, J., Schiliro, G., Wajcman, H., Labie, D., Moo-Penn, W., and Castro, O. (1980) Nature 283, 832-834[Medline] [Order article via Infotrieve]
11. Benesch, R. E., Kwong, S., Benesch, R., and Edalji, R. (1977) Nature 269, 772-775[Medline] [Order article via Infotrieve]
12. Benesch, R. E., Yung, S., Benesch, R., Mack, J., and Schneider, R. (1976) Nature 260, 219-222[Medline] [Order article via Infotrieve]
13. Manning, J. M. (1991) Adv. Enzymol. Relat. Areas Mol. Biol. 64, 55-91[Medline] [Order article via Infotrieve]
14. Rao, M. J., Iyer, K. S., and Acharya, A. S. (1995) J. Biol. Chem. 33, 19250-19255[CrossRef]
15. Adachi, K., Reddy, L. R., Reddy, K. S., and Surrey, S. (1995) Protein Sci. 4, 1272-1278[Abstract/Free Full Text]
16. Ho, C., Willis, B. F., Shen, T. J., Ho, N. T., Sun, D. P., Tam, M. F., Suzuka, S. M., Fabry, M. E., and Nagel, R. L. (1996) J. Mol. Biol. 263, 475-485[CrossRef][Medline] [Order article via Infotrieve]
17. Himanen, J.-P., Schneider, K., Chait, B. T., and Manning, J. M. (1995) J. Biol. Chem. 23, 13885-13891[CrossRef]
18. Himanen, J.-P., Popowicz, A. M., and Manning, J. M. (1997) Blood 89, 4196-4203[Abstract/Free Full Text]
19. Li, X., Mirza, U. A., Chait, B. T., and Manning, J. M. (1997) Blood 90, 4620-4627[Abstract/Free Full Text]
20. Manning, J. M., Dumoulin, A., Li, X., and Manning, L. R. (1998) J. Biol. Chem. 273, 19359-19362[Free Full Text]
21. Benesch, R. E., Kwong, S., and Benesch, R. (1982) Nature 299, 231-234[Medline] [Order article via Infotrieve]
22. Rhoda, M. D., Blouquit, Y., Caburi-Martin, J., Monplasir, N., Galacteros, F., Garel, M. C., and Rosa, J. (1984) Biochim. Biophys. Acta 786, 62-64[Medline] [Order article via Infotrieve]
23. Kraus, L. M., Miyaji, T., Iuchi, I., and Kraus, A. P. (1966) Biochemistry 5, 3701-3708[Medline] [Order article via Infotrieve]
24. Nagel, R. L., and Bookchin, R. M. (1978) in Biological and Clinical Aspects of Hemoglobin Abnormalities (Caughey, W. S., ed) , pp. 195-201, Academic Press, New York
25. Guis, M., Mentzer, W. C., Jue, D. L., Johnson, M. H., McGuffey, J. E., and Moo-Penn, W. F. (1985) Hemoglobin 9, 175-177[Medline] [Order article via Infotrieve]
26. Roy, R. P., and Acharya, A. S. (1994) Methods Enzymol. 231, 194-215[Medline] [Order article via Infotrieve]
27. Maita, T., Hayashida, M., and Matsuda, G. (1984) J. Biochem. (Tokyo) 95, 805-813[Abstract]
28. Bucci, E. (1981) Methods Enzymol. 76, 97-105[Medline] [Order article via Infotrieve]
29. Kaiser, E., Colescott, R. L., Bossinger, C. D., and Cook, P. I. (1970) Anal. Biochem. 84, 595-598
30. Bookchin, R. M., Balazs, T., Wang, Z., Josephs, R., and Lew, V. L. (1999) J. Biol. Chem. 274, 6689-6697[Abstract/Free Full Text]
31. Adachi, K., and Asakura, T. (1979) J. Biol. Chem. 254, 4079-4084[Abstract]
32. Adachi, K., and Asakura, T. (1979) J. Biol. Chem. 254, 7765-7771[Medline] [Order article via Infotrieve]
33. Briehl, R. W., and Hobbs, J. F. (1970) J. Biol. Chem. 245, 544-554[Abstract/Free Full Text]
34. Imai, K. (1973) Biochemistry 12, 128-134[Medline] [Order article via Infotrieve]
35. Imai, K., Tsuneshige, A., Harano, T., and Harano, K. (1989) J. Biol. Chem. 264, 11174-11180[Abstract/Free Full Text]
36. Liang, C.-C., Chen, S., Yang, K., Jia, P., Ma, Y., Li, T., Ni, X., Wang, X., Dang, Q., and Yao, S. (1982) Hemoglobin 6, 629-633[Medline] [Order article via Infotrieve]
37. Harrington, D. J., Adachi, K., and Royer, W. E., Jr. (1997) J. Mol. Biol. 272, 398-407[CrossRef][Medline] [Order article via Infotrieve]
38. Rao, M. J., Malavalli, A., Manjula, B. N., Kumar, R., Prabhakaran, M., Sun, D. P., Ho, N. T., Ho, C., Nagel, R. L., and Acharya, A. S. (2000) J. Mol. Biol. 300, 1389-1406[CrossRef][Medline] [Order article via Infotrieve]
39. Roy, R. P., Nagel, R. L., and Acharya, A. S. (1993) J. Biol. Chem. 268, 16406-16412[Abstract/Free Full Text]
40. Nacharaju, P., Roy, R. P., White, S. P., Nagel, R. L., and Acharya, A. S. (1997) J. Biol. Chem. 272, 27869-27876[Abstract/Free Full Text]
41. Himanen, J.-P., Mirza, U. A., Chait, B. T., Bookchin, R. M., and Manning, J. M. (1996) J. Biol. Chem. 271, 25152-25156[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.